Tesamorelin and the New Race to Lose the Right Fat

The latest bet in obesity medicine is not just on making people lighter. It is on being more selective about what they lose.

On October 13, Roche licensed an experimental ALK7-targeting RNA interference therapy from Rona Therapeutics. Its proposed advantage: reduce visceral and other ectopic fat while preserving lean mass. Those are development goals, not human efficacy results. The agreement concerns a different treatment—not tesamorelin—but puts a familiar question into sharper focus. 1

What counts as successful fat loss when the scale barely moves?

Tesamorelin already has a clinical answer to part of that question. It is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its prescribing information also says it is not indicated for weight-loss management because its effect is weight-neutral. Those statements are not contradictory: changing body composition and losing weight are different outcomes. 2

The more ambitious question is whether a useful change in tissue becomes a useful change in ability. That is where tesamorelin’s next chapter gets interesting.

A fat-loss result hiding inside a weight-neutral drug

Visceral fat sits deep in the abdomen around internal organs. Subcutaneous fat lies beneath the skin. Fat can also accumulate within tissues such as muscle. Treating all of these compartments as one measure of belly size misses what researchers are actually examining. 3

Tesamorelin acts through the growth-hormone system. It mimics a releasing signal that prompts the pituitary to secrete growth hormone, increasing IGF-1, a downstream growth-related signal. It does not use the same mechanism as the RNAi candidate in the Roche agreement. 2 1

In a 2007 randomized trial, 412 adults with HIV and abdominal fat accumulation received tesamorelin or placebo. Over 26 weeks, the visceral-fat measurement fell 15.2% with tesamorelin and rose 5.0% with placebo. Most participants were men. These were changes in the measured visceral-fat compartment—not total body weight or waist circumference. 4

The noun after the percentage matters. Replace visceral fat with weight and the result becomes easier to sell but wrong. Keep it attached, and a more useful story appears: the body can change in ways the bathroom scale cannot adequately describe.

Two 2026 reviews bring the pattern into focus

A meta-analysis published online January 16 pooled five randomized trials in adults with HIV. It found less visceral and trunk fat and more lean body mass with tesamorelin. The pooled lean-mass difference was 1.42 kilograms, with a 95% confidence interval of 1.13–1.71 kilograms. Yet there was no significant reduction in body mass index or subcutaneous adipose tissue. 5

That is not a failure to agree with the scale. It is a reason to stop asking the scale to explain every treatment effect.

A second review, published July 31, included four trials and a reported 909 participants. It found a similar body-composition pattern while emphasizing limited long-term evidence and growth-hormone-related adverse effects. The two reviews synthesize earlier trials; they should not be counted as two wholly new groups of patients. 6

These pooled findings concern HIV-associated lipodystrophy. They do not establish the same benefit for everyone with abdominal fat. And an increase in measured lean body mass is not automatically the same increase in working skeletal muscle. The distinction between a favorable measurement and a useful ability is the next problem to solve. 5 3

A better-looking muscle still has to do something

A secondary analysis published in a 2019 journal issue examined muscle CT images from earlier trials. It compared 193 tesamorelin responders—people whose visceral fat fell at least 8%—with 148 placebo recipients. Muscle-density findings were consistent with less fat within muscle, and some muscle-area measurements improved. 3

There is a catch worth keeping visible: selecting responders is not the same as comparing everyone as originally randomized. Nor did those images establish better everyday physical function. The findings supplied a reason to test movement, not permission to assume it had improved. 3

Imagine two people whose scans show the same amount of lean tissue. One rises easily from a chair; the other needs help. The measurement matters, but it has not described the whole difference between them. This is an illustration of why function deserves its own test, not a comparison made by that study.

For recovery research, the opportunity is substantial. Instead of asking whether an intervention merely adds or removes tissue, ask whether it changes what that tissue allows a person to do.

The next test is ten chair stands

The TRIUMPH protocol, published July 8 in BMJ Open, plans a trial of 100 sedentary adults aged 50–80 living with HIV, excess abdominal adiposity and frailty or signs of it. Participants receive tesamorelin or placebo alongside home-based exercise for 24 weeks. Another 24 weeks follow off study drug, with independent exercise encouraged. 7

The primary endpoint is the percentage change in the time needed to complete ten repeated chair stands. It asks whether the drug adds benefit during an exercise program—not whether an injection can replace exercise. 7

The chair is not a less sophisticated endpoint than the scan. It answers a different question. A biological explanation becomes more valuable when it helps explain a change that a person can use.

This is a protocol, not a successful result. Recruitment began in July 2025, according to the paper. The National Institute on Aging funds the study; the manufacturer provides reduced-price product, and investigator industry relationships are disclosed. 7

The harder result is the one that lasts

Tesamorelin’s history makes the off-drug phase important. In a 404-person trial published in 2010, participants initially receiving the drug were later randomized to continue it or switch to placebo. Visceral-fat improvements were rapidly lost after the switch; continued treatment maintained reductions. 8

That does not tell us what exercise-supported treatment will accomplish. It identifies the hurdle a durable strategy must clear.

A benefit that requires continuing treatment can still be worthwhile. But it is a different proposition from an improvement that remains after a course ends. Cost, tolerability, daily effort and the value of the outcome all belong in that comparison.

The meaningful question is not whether patients can be photographed at a favorable moment. It is what happens after that moment—and what keeping the benefit requires.

Where the billion-dollar bet fits

The Roche–Rona deal allows up to $100 million in upfront and near-term milestone payments, plus up to $1.06 billion in later milestones, with royalties extra. That totals a potential $1.16 billion. It is not money already paid for demonstrated patient benefit, and it is not a valuation of tesamorelin. 1

There is a separate scientific rationale for the licensed target. A genetic study of more than 400,000 UK Biobank participants linked variation in ACVR1C, the gene encoding ALK7, with differences in fat distribution. Inherited variation is not a clinical trial of a drug that silences the target, but it provides a reason to investigate. 9

The connection between the programs is a clinical ambition, not a claim that Roche bought the same idea in another vial. An older hormone-signaling therapy and a new RNA-based candidate can illuminate the same question without being interchangeable.

For developers, better body composition offers a possible way to distinguish a treatment. For patients, that distinction needs to survive a more demanding test: does it produce an outcome worth the cost and burden? A licensing agreement reveals an investment priority. It does not establish what a medicine will accomplish or what someone will pay at the pharmacy.

Even small improvements in delivery deserve accurate language. The Egrifta WR formulation approved in March 2025 reduced preparation to once a week while retaining daily injections. Weekly preparation is not weekly dosing. That reformulation did not create a new general weight-loss indication. 10

Making treatment easier to use and making it work better are separate achievements. Both matter; neither should be assumed from the other.

A better finish line than a lower number

Tesamorelin has real clinical evidence, not immunity from risk. Its labeling warns about elevated IGF-1, fluid retention and glucose intolerance or diabetes. Active malignancy and pregnancy are among its contraindications, and long-term cardiovascular safety has not been established. 2

Those concerns belong in the same assessment as the potential benefit. A positive body-composition result does not make the rest of the person disappear.

The October licensing news gives this older peptide a timely context. Fat location, retained tissue, physical ability and durability are different ways to judge a treatment. A serious development program has to decide which it is improving—and show its work.

For tesamorelin, the next persuasive finding would not need to be the largest percentage on a weight-loss chart. It could be a worthwhile improvement in movement, accompanied by evidence explaining who benefits and whether that benefit lasts.

The next meaningful result may be measured not in pounds lost, but in how easily someone gets out of a chair.

---

Read next: How Recovery Science Digest evaluates research.

Evidence note: This is science and business news analysis, checked October 19, 2026. The new event is the October 13 licensing agreement, not a new tesamorelin outcome report. Some older trials and the 2026 reviews were available as abstracts; the protocol and muscle-analysis methods were examined in original full or indexed text. No interviews were conducted. This AI-assisted article has not yet received independent scientific or clinical review and is not individualized treatment advice.

Sources

1. Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy. 2026-10-13.
2. EGRIFTA WR prescribing information. Label text revised 2025-03; DailyMed record updated 2026-07-29.
3. The GHRH analogue tesamorelin decreases muscle fat and increases muscle area in adults with HIV. 2018-12-14 online; 2019-07 issue. DOI: 10.14283/jfa.2018.45.
4. Metabolic effects of a growth hormone-releasing factor in patients with HIV. 2007-12-06. DOI: 10.1056/NEJMoa072375.
5. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin: meta-analysis. 2026-01-16. DOI: 10.1016/j.orcp.2026.01.002.
6. Efficacy and Safety of Tesamorelin in People Living With HIV With Lipodystrophy. 2026-07-31. DOI: 10.1177/23259582261475549.
7. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): protocol. 2026-07-08. DOI: 10.1136/bmjopen-2026-120740.
8. Effects of tesamorelin in HIV with abdominal fat: randomized study with safety extension. 2010-03. DOI: 10.1097/QAI.0b013e3181cbdaff.
9. DNA sequence variation in ACVR1C influences body fat distribution and protects against type 2 diabetes. 2018-11-02 online; 2019-01 issue. DOI: 10.2337/db18-0857.
10. FDA approval of EGRIFTA WR. 2025-03-25.